Author Archives: ino_admin
BioCentury is featuring Inositec in this week’s emerging company profile. Read the article here (requires subscription).
Scrip Intelligence interviewed Mattias Ivarsson at BIO Europe 2016 in Cologne. The video can be found here.
Inositec AG Secures CHF1.4 million in Seed Financing to Advance New Class of Inositol Hexaphosphate-Based Drug Candidates
Lead programs address unmet medical needs in vascular calcification and C. difficile infection Zurich, Switzerland, 27th October 2016 – Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a … Continue reading
Inositec has been short-listed together with 10 nominees for the deVigier prize. More info here. 29th March 2016
Mattias Ivarsson appeared in the Science and Healthcare category of the 2016 Forbes 30 under 30 European list. 1st March 2016
Mattias Ivarsson has a vision: he wants to keep a dangerous pathogen in check using an innovative approach. As a Pioneer Fellow, he is now taking his first steps on the path to making that vision a reality. Click here for … Continue reading
Three Zurich-based start-ups were awarded this year’s Heuberger Winterthur Start-up Award. The three companies from the Life Sciences field each received CHF 150,000 in prize money. Three other start-ups were awarded CHF 50,000 each. Click here for an article and … Continue reading
Check out the newsflash, the >>venture>> website or our video for more information. 18th June 2015
Mattias Ivarsson is committed to fighting a nasty bacterium at the root of many hospital-acquired infections. This article describes the story behind Inositec’s technology and CEO. 10th November 2014
Swiss national radio interviews Mattias Ivarsson about Inositec’s therapeutic approach to treat Clostridium difficile infection (in French). Audio link 6th November 2014